Arrhythmia/EP
Expanding Role of HF-Device Therapy?
Sep 28, 2009 14:20 EDT
The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.
Acknowledgements
CME provider: Medscape, LLC.
The Arrhythmia Management and Electrophysiology clinical theme is supported by an independent educational grant from Medtronic.
button
Steering committee
The steering committee members are active in overseeing the development and direction of this educational series.

Gregg C. Fonarow, MD
David L. Hayes, MD
Robert C. Kowal, MD
Francis E. Marchlinski, MD
Eric N. Prystowsky, MD
Previews
Featured CME
View all CME programs >>
Resource center
ARRHYTHMIA/EP
A venue for information, slides, articles, tools, and support material for physicians and healthcare providers.
Poll
The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.

How do you think the results of the MADIT-CRT trial (and other studies suggesting benefits of CRT device-based therapy in earlier-stage HF patients) will affect implant CRT rates in the next 3 years?
See: MADIT-CRT: Resynchronization therapy cuts heart-failure risk in patients with only mild disease
Rates will significantly increase (> 15% increase in primary prevention ICD utilization in congestive HF patients)
Rates will moderately increase (5%-10%)
Rates will slightly increase (2%-5%)
Rates will slightly increase (2%-5%)

Vote